查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344325

病毒载体製造市场：依病毒载体类型、适应症、应用划分：2023-2032 年全球机会分析与产业预测

Viral Vector Production Market By Viral Vector Type, By Indication, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 286 Pages | 商品交期: 2-3个工作天内

价格

由于诊断和生物技术领域的市场需求不断增加，病毒载体製造市场预计在 2023 年至 2032 年期间将显着增长 18.8%。

病毒载体生产市场-IMG1

病毒载体是在基因治疗和疫苗开发中用于将遗传物质传递到目标细胞的工具。 载体源自天然存在的病毒，这些病毒经过修饰以消除其引起疾病的能力，同时保留有效进入细胞并传递所需遗传物质的能力。 病毒载体被设计为携带治疗基因，例如缺陷或突变基因，并将它们引入患者的细胞中。

载体充当递送载体，将遗传物质运送到目标细胞，在目标细胞中表达并产生所需的治疗效果。 几种类型的病毒通常用作病毒载体，包括腺病毒、腺相关病毒（AAV）、慢病毒和逆转录病毒。 每种类型的病毒载体都具有独特的特征，并根据目标细胞类型和所需的基因表现持续时间等因素进行选择。

在病毒载体製造过程中，病毒基因组被修改以移除致病元件并插入所需的治疗基因。 修饰的病毒载体透过细胞培养或其他製造方法大量生产。 进行品质控制以确保病毒载体产品的安全性、效力和纯度。

全球遗传疾病的日益普及是病毒载体製造市场成长的主要驱动力。 肌肉营养不良症、囊性纤维化和血友病等遗传疾病影响着全世界许多人。 例如，根据美国血友病基金会（2023）的数据，美国有 30,000 至 33,000 名血友病患者。 基因疗法为这些疾病的治疗提供了有希望的可能性，提供了治癒或长期治疗选择的可能性。

此外，病毒载体在基因治疗中发挥重要作用，因为它们充当载体，将治疗基因传递到目标细胞并纠正潜在的遗传缺陷。 医疗保健专业人员和患者对基因治疗的认识和知识不断提高，导致对病毒载体製造的需求增加。

目录

第一章简介

第 2 章执行摘要

第三章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态
    • 促进因素
      • 癌症、传染病和遗传疾病的盛行率不断上升
      • 对基因治疗的需求与认知不断提高
      • 市场领导者采用的策略激增
    • 抑制因素
      • 与病毒载体生产相关的高成本
      • 病毒载体生产的监管要求
    • 机会
      • 基因治疗与病毒疫苗领域的强大研发管线
  • 新冠肺炎 (COVID-19) 市场影响分析

第 4 章病毒载体製造市场：依病毒载体类型

  • 摘要
  • 腺病毒载体
  • 慢病毒载体
  • 逆转录病毒载体
  • 腺相关病毒载体
  • 其他病毒载体

第五章病毒载体製造市场：按适应症

  • 摘要
  • 癌症
  • 遗传疾病
  • 传染病
  • 其他疾病

第六章病毒载体製造市场：依应用划分

  • 摘要
  • 基因治疗
  • 疫苗治疗

第七章病毒载体製造市场：依地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第八章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第九章公司简介

  • Andelyn Biosciences
  • Charles River Laboratories
  • Danaher Corporation
  • FinVector Oy
  • Lonza
  • Oxford Biomedica
  • TAKARA HOLDINGS INC.
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Avid Bioservices, Inc.
Product Code: A13615

The viral vector production market is likely to experience a significant growth rate of 18.8% from 2023-2032 owing to increasing market demand from diagnostic and biotech sector - Allied Market Research

Viral Vector Production Market - IMG1

Viral vectors are tools used in gene therapy and vaccine development to deliver genetic material into target cells. They are derived from naturally occurring viruses that have been modified to remove their disease-causing ability while retaining their ability to efficiently enter cells and deliver the desired genetic material. Viral vectors are designed to carry and introduce therapeutic genes, such as missing or mutated genes, into the cells of patients.

They act as delivery vehicles, transporting the genetic material to the target cells where it may be expressed and produce the desired therapeutic effect. Several types of viruses are commonly used as viral vectors, including adenoviruses, adeno-associated viruses (AAV), lentiviruses, retroviruses, and others. Each type of viral vector has unique characteristics and is selected on the basis of factors such as the target cell type, the desired duration of gene expression and others.

The viral vector production process involves modifying the viral genome to remove disease-causing elements and inserting the therapeutic gene of interest. The modified viral vector is then produced in enormous quantities through cell culture or other manufacturing methods. Quality control measures are implemented to ensure the safety, potency, and purity of the viral vector product.

The increase in prevalence of genetic disorders worldwide is a significant driving force behind the growth of the viral vector production market. Genetic conditions such as muscular dystrophy, cystic fibrosis, and hemophilia impact a large number of individuals globally. For instance, National Hemophilia Foundation (2023) there are between 30,000 to 33,000 people who live with hemophilia in the U.S. Gene therapy offers promising potential for treatment of these disorders, providing the possibility of a cure or long-term treatment options.

Moreover, viral vectors play a crucial role in gene therapy as they act as carriers, delivering therapeutic genes into the targeted cells to correct the underlying genetic defects. The growth in awareness and knowledge about gene therapy among healthcare professionals and patients has contributed to the rise in demand for viral vector production.

In addition, the global incidence of cancer has been on the rise, with a substantial number of new cases being diagnosed annually. This alarming trend has spurred significant interest in innovative treatment modalities, and viral vectors have emerged as pivotal components in gene therapy strategies for combating cancer. These specialized vectors have the ability to transport therapeutic genes or induce modifications in target cells, thereby amplifying immune responses against cancerous cells.

In addition, viral vector platforms play a critical role in the advancement of oncolytic viral therapies, which utilize viruses to directly target and eradicate cancer cells. The increase in demand for effective cancer treatments serves as a driving force behind the growth in need for viral vectors and their production. Furthermore, the COVID-19 pandemic has led to a significant rise in viral vector production for vaccine development.

Viral vectors, such as adenoviruses, have been utilized as a platform for the development of COVID-19 vaccines. These vectors are engineered to carry the genetic material of the SARS-CoV-2 spike protein, stimulating an immune response in vaccinated individuals. The urgent need for effective vaccines to combat the global health crisis has accelerated the production of viral vectors and thus contributed significantly to the growth of the market.

However, the viral vector production market faces certain restraints that may impede its growth and development. One significant restraint is the excessive cost associated with viral vector production. The manufacturing process requires substantial upfront capital investment, specialized infrastructure, and skilled personnel. In addition, the use of expensive raw materials and quality control measures further escalates production costs. These high costs may limit accessibility and affordability of gene therapies and viral vector-based vaccines, hindering the wider adoption and market growth.

On the contrary, the viral vector production market presents significant opportunities for growth and innovation. The increase in adoption of gene therapies and viral vector-based vaccines, coupled with the expanding pipeline of promising candidates, fuels the demand for viral vectors. Advancements in vector engineering, manufacturing technologies, and process optimization create opportunities for more efficient and cost-effective production.

Furthermore, developing regions present significant opportunities for growth in the viral vector production market. Rise in healthcare expenditures, developing healthcare infrastructure, government initiatives and support for treatment of complex diseases is further anticipated to boost the demand for viral vector production in this region.

The global viral vector production market is segmented based on viral vector type, indication, application, end user, and region. On the basis of viral vector type, the market is categorized into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral, and other viral vectors. On the basis of indication, it is segregated into cancer, genetic disorders, infectious diseases, and other diseases. On the basis of application, it is bifurcated into gene therapy, and vaccinology.

On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Andelyn Biosciences, Charles River Laboratories, Danaher Corporation., FinVector Oy, Lonza, Novartis AG, Oxford Biomedica plc, Takara Holdings Inc., Thermo Fisher Scientific Inc. and Avid Bioservices, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the viral vector production market analysis from 2022 to 2032 to identify the prevailing viral vector production market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the viral vector production market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global viral vector production market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Other Diseases

By Application

  • Gene Therapy
  • Vaccinology

By Viral Vector Type

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Adeno-Associated Viral Vectors
  • Other Viral Vectors

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Andelyn Biosciences
    • Avid Bioservices, Inc.
    • Charles River Laboratories
    • Danaher Corporation
    • FinVector Oy
    • Lonza
    • Novartis AG
    • Oxford Biomedica
    • TAKARA HOLDINGS INC.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cancer, infectious diseases, and genetic disorders
      • 3.4.1.2. Increase in demand and awareness for gene therapy
      • 3.4.1.3. Surge in number of strategies adopted by market key players
    • 3.4.2. Restraints
      • 3.4.2.1. High cost associated with viral vector production
      • 3.4.2.2. Regulatory Requirements for viral vector production
    • 3.4.3. Opportunities
      • 3.4.3.1. Robust pipeline in gene therapy and viral vaccines
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Adenoviral Vectors
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Lentiviral Vectors
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Retroviral Vectors
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Adeno-Associated Viral Vectors
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other Viral Vectors
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: VIRAL VECTOR PRODUCTION MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Genetic Disorders
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Infectious Diseases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Other Diseases
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Gene Therapy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Vaccinology
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: VIRAL VECTOR PRODUCTION MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Viral Vector Type
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Viral Vector Type
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Viral Vector Type
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Viral Vector Type
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Viral Vector Type
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Viral Vector Type
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Viral Vector Type
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Viral Vector Type
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Application
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Viral Vector Type
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Viral Vector Type
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Application
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Viral Vector Type
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Application
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Viral Vector Type
      • 7.5.5.3.3. Market size and forecast, by Indication
      • 7.5.5.3.4. Market size and forecast, by Application
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Viral Vector Type
      • 7.5.5.4.3. Market size and forecast, by Indication
      • 7.5.5.4.4. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Andelyn Biosciences
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Key strategic moves and developments
  • 9.2. Charles River Laboratories
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Danaher Corporation
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. FinVector Oy
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Key strategic moves and developments
  • 9.5. Lonza
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Oxford Biomedica
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. TAKARA HOLDINGS INC.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Thermo Fisher Scientific Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Novartis AG
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Avid Bioservices, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 02. VIRAL VECTOR PRODUCTION MARKET FOR ADENOVIRAL VECTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. VIRAL VECTOR PRODUCTION MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. VIRAL VECTOR PRODUCTION MARKET FOR RETROVIRAL VECTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. VIRAL VECTOR PRODUCTION MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. VIRAL VECTOR PRODUCTION MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 08. VIRAL VECTOR PRODUCTION MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. VIRAL VECTOR PRODUCTION MARKET FOR GENETIC DISORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. VIRAL VECTOR PRODUCTION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. VIRAL VECTOR PRODUCTION MARKET FOR OTHER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. VIRAL VECTOR PRODUCTION MARKET FOR GENE THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. VIRAL VECTOR PRODUCTION MARKET FOR VACCINOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. VIRAL VECTOR PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA VIRAL VECTOR PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE VIRAL VECTOR PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 41. UK VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 44. ITALY VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 60. CHINA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 63. INDIA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA VIRAL VECTOR PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. ANDELYN BIOSCIENCES: KEY EXECUTIVES
  • TABLE 90. ANDELYN BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 91. ANDELYN BIOSCIENCES: SERVICE SEGMENTS
  • TABLE 92. ANDELYN BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 93. ANDELYN BIOSCIENCES: KEY STRATERGIES
  • TABLE 94. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
  • TABLE 95. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
  • TABLE 96. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
  • TABLE 97. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 98. CHARLES RIVER LABORATORIES: KEY STRATERGIES
  • TABLE 99. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 100. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 101. DANAHER CORPORATION: PRODUCT SEGMENTS
  • TABLE 102. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 103. DANAHER CORPORATION: KEY STRATERGIES
  • TABLE 104. FINVECTOR OY: KEY EXECUTIVES
  • TABLE 105. FINVECTOR OY: COMPANY SNAPSHOT
  • TABLE 106. FINVECTOR OY: PRODUCT SEGMENTS
  • TABLE 107. FINVECTOR OY: SERVICE SEGMENTS
  • TABLE 108. FINVECTOR OY: PRODUCT PORTFOLIO
  • TABLE 109. FINVECTOR OY: KEY STRATERGIES
  • TABLE 110. LONZA: KEY EXECUTIVES
  • TABLE 111. LONZA: COMPANY SNAPSHOT
  • TABLE 112. LONZA: PRODUCT SEGMENTS
  • TABLE 113. LONZA: SERVICE SEGMENTS
  • TABLE 114. LONZA: PRODUCT PORTFOLIO
  • TABLE 115. LONZA: KEY STRATERGIES
  • TABLE 116. OXFORD BIOMEDICA: KEY EXECUTIVES
  • TABLE 117. OXFORD BIOMEDICA: COMPANY SNAPSHOT
  • TABLE 118. OXFORD BIOMEDICA: PRODUCT SEGMENTS
  • TABLE 119. OXFORD BIOMEDICA: SERVICE SEGMENTS
  • TABLE 120. OXFORD BIOMEDICA: PRODUCT PORTFOLIO
  • TABLE 121. TAKARA HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 122. TAKARA HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 123. TAKARA HOLDINGS INC.: PRODUCT SEGMENTS
  • TABLE 124. TAKARA HOLDINGS INC.: PRODUCT PORTFOLIO
  • TABLE 125. TAKARA HOLDINGS INC.: KEY STRATERGIES
  • TABLE 126. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
  • TABLE 127. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
  • TABLE 128. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
  • TABLE 129. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
  • TABLE 130. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
  • TABLE 131. THERMO FISHER SCIENTIFIC INC. : KEY STRATERGIES
  • TABLE 132. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 133. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 134. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 135. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 136. AVID BIOSERVICES, INC.: KEY EXECUTIVES
  • TABLE 137. AVID BIOSERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 138. AVID BIOSERVICES, INC.: SERVICE SEGMENTS
  • TABLE 139. AVID BIOSERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 140. AVID BIOSERVICES, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. VIRAL VECTOR PRODUCTION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF VIRAL VECTOR PRODUCTION MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN VIRAL VECTOR PRODUCTION MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALVIRAL VECTOR PRODUCTION MARKET
  • FIGURE 09. VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR ADENOVIRAL VECTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR RETROVIRAL VECTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. VIRAL VECTOR PRODUCTION MARKET, BY INDICATION, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR GENETIC DISORDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR OTHER DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION, 2022(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR GENE THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR PRODUCTION MARKET FOR VACCINOLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. VIRAL VECTOR PRODUCTION MARKET BY REGION, 2022
  • FIGURE 24. U.S. VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA VIRAL VECTOR PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: VIRAL VECTOR PRODUCTION MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. CHARLES RIVER LABORATORIES: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. LONZA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. LONZA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. LONZA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. OXFORD BIOMEDICA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. OXFORD BIOMEDICA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. OXFORD BIOMEDICA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. TAKARA HOLDINGS INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. TAKARA HOLDINGS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. THERMO FISHER SCIENTIFIC INC. : NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. AVID BIOSERVICES, INC.: NET SALES, 2020-2022 ($MILLION)